GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Other Stockholders Equity

Cue Biopharma (Cue Biopharma) Other Stockholders Equity : $-0.00 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Other Stockholders Equity?

Cue Biopharma's Other Stockholders Equity for the quarter that ended in Dec. 2023 was $-0.00 Mil.

Cue Biopharma's quarterly Other Stockholders Equity declined from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) and declined from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Cue Biopharma's annual Other Stockholders Equity declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil) and declined from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($-0.00 Mil).


Cue Biopharma Other Stockholders Equity Historical Data

The historical data trend for Cue Biopharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Other Stockholders Equity Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only - - - - -

Cue Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cue Biopharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Cue Biopharma Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma (Cue Biopharma) Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Executives
Anish Suri officer: President and CSO 40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri director, officer: CEO 40 GUEST STREET, BOSTON MA 02135
Pamela Garzone director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti officer: Chief Medical Officer C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn officer: Chief Business Officer C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar officer: CFO 40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta officer: Chief Medical Officer C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin officer: SVP, General Counsel and Sec 40 GUEST STREET, BOSTON MA 02135
Tamar D Howson director
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll director

Cue Biopharma (Cue Biopharma) Headlines